RuiYi YaoDa Achieves Over RMB 100 Million Revenue Within One Year of Founding, Unveiling a New Business Model in Pharma Innovation Services

In the field of pharmaceutical innovation services, how can a company rapidly achieve annual revenues exceeding RMB 100 million? Many practitioners might instinctively answer by “selling drugs” through pharmaceutical e-commerce. However, for SOPHMED, the answer is not so straightforward.

As an innovative service company adhering to the principle of “not selling drugs,” SOPHMED achieved annual revenue exceeding RMB 100 million within one year of its establishment in early 2022, thanks to its unique and innovative business model. Zhan Haitao, Founder and Chairman of SOPHMED, stated, “We project that this year’s revenue will be several times higher than last year’s…”

Zhan Haitao, Founder and Chairman of SOPHMED

So, how does SOPHMED achieve this?

Advancing the development of a multi-tiered medical security system and paving new pathways for the growth of innovative drugs have become industry trends. In 2021, the National Development and Reform Commission issued the “14th Five-Year Plan for Bioeconomy Development,” which stated that policies related to new drug review, medical insurance reimbursement, and clinical use should be improved to accelerate the commercialization of approved innovative drugs and foster a virtuous cycle in which enterprises achieve innovation-driven growth through returns on innovation. Meanwhile, building a “multi-tiered medical security system with Chinese characteristics” has once again emerged as a key topic at this year’s Two Sessions.

Currently, China’s pharmaceutical innovation industry has evolved from “scale expansion” to “quality improvement and efficiency enhancement,” with “homogeneous competition” and profitability falling short of expectations becoming common challenges. Pharmaceutical innovation enterprises need to explore their differentiated advantages, accelerate the commercialization of innovative products, and use the returns from innovation to reinvest in the research and development of new, high-quality innovative products.

On the other hand, population aging has rendered the basic coverage model of medical insurance insufficient to meet the growing healthcare demands. The increasing demand for multi-tiered protection, including health management and innovative drugs, has spurred greater vitality in the pharmaceutical innovation market.

As laws and regulations pertaining to innovative drugs continue to be refined, “compliance” has become an unavoidable topic. This encompasses not only the compliance of pharmaceutical companies in drug research and development, manufacturing, and sales, but also the compliance of the overall ecosystem of their collaborative industries.

SOPHMED was established to provide enterprises with integrated growth solutions while ensuring compliance, thereby better helping innovative pharmaceutical companies navigate current transformations and achieve commercial value conversion. It also aims to better serve patients by meeting their multi-layered protection needs. “We position ourselves as a bridge and link among pharmaceutical companies, healthcare institutions, and payers, dedicated to serving both pharmaceutical companies and patients to enhance the market accessibility of innovative drugs,” said Zhan Haitao, Chairman of SOPHMED.

Against this backdrop, SOPHMED has strategically focused on three core business segments: innovative payment and patient management, digital marketing, and digital clinical trials. In light of this strategic layout, Wei Tian, Co-founder and CEO of SOPHMED, stated:

Wei Tian, Co-founder and CEO of SOPHMED

First, pharmaceutical companies have business needs in innovative payment and patient management, digital marketing, and digital clinical trials, indicating significant market potential. Meanwhile, SOPHMED is one of the few companies that have innovatively integrated these three business areas and put them into practice. SOPHMED aims to further improve and promote industry development as an innovative integrator.

Second, SOPHMED is committed to addressing the diverse needs of innovative pharmaceutical companies at different stages. For instance, early-stage biotech firms require accelerated clinical research efficiency, whereas large listed pharmaceutical companies and multinational corporations are more in need of innovative payment solutions combined with patient management services to help extend patients’ duration of therapy (DOT) and alleviate their financial burden. This is particularly critical for high-priced innovative drugs; given patients’ limited ability to pay, commercial insurance models featuring innovative payment mechanisms are essential to improve the accessibility and affordability of these medications.

Patient needs define the market. SOPHMED is committed to building an innovative ecosystem that provides patients with convenient access to affordable, high-quality innovative drugs, enabling them to benefit from superior, multi-tiered healthcare coverage services.

SOPHMED’s rapid development is evident to all in the industry. Its ability to achieve self-sustainability and revenue growth is a testament to the recognition of its capabilities by both the industry and its clients.

In the innovative payment and patient management sector, SOPHMED helped a listed innovative pharmaceutical company achieve a 30% sales growth, served over 15,000 patients, and reached a project scale of more than RMB 200 million. In the digital marketing sector, SOPHMED provided professional digital academic services to over 60,000 experts, helping a listed innovative pharmaceutical company improve operational efficiency. Through its digital clinical research services, SOPHMED tripled the patient enrollment efficiency in clinical trials and reduced subject dropout rates by 300%, securing signing collaborations with multiple biotech companies.

Based on its previous achievements, SOPHMED is also considering accelerating its business expansion. As Zhan Haitao, Chairman of SOPHMED, stated, “With regard to financing, we prefer to introduce strategic investors whose businesses align with ours and who can help us achieve business expansion. The funds raised will be further invested in R&D and the development of AI products for vertical sectors.”

From a business perspective, SOPHMED plans to further expand its capabilities in digital marketing operations, data governance, and AI integration. By leveraging data decision models and large language models, the company aims to generate precise user profiles, empower both enterprises and patients, and provide comprehensive, full-lifecycle solutions. Additionally, SOPHMED will further explore the integration of supplementary medical insurance with commercial insurance, offering supplemental health insurance and other insurance models to provide more effective solutions for improving drug accessibility and enhancing patients’ ability to pay.

In practice, the three core business segments will serve as SOPHMED’s strategic levers to drive a transition from quantitative expansion to qualitative transformation. The rapid growth in the number of patients participating in innovative payment models and physicians engaged in digital marketing will further fuel the expansion of its digital clinical research business, ultimately achieving efficient integration and sustainable development across the entire ecosystem.

“From the perspective of pharmaceutical companies, SOPHMED addresses pain points related to drug accessibility and patient management, while also providing enterprises with an effective digital marketing solution that offers greater patient support for their product pipelines. From the patient’s perspective, digital marketing delivers better disease education and improved patient management programs, whereas innovative payment solutions help alleviate the financial burden of medication costs. When patients, particularly those with oncology-related conditions, experience disease progression, digital clinical trials offer new therapeutic possibilities,” added Wei Tian, Co-founder and CEO of SOPHMED.

Pharmaceutical innovation in China serves as a crucial guarantee for the sustainable development of public health. SOPHMED has also expressed its unwavering commitment to safeguarding people’s health, and will actively collaborate to promote the global expansion of Chinese innovative drugs, thereby enhancing the international strategic standing of China’s pharmaceutical innovation industry.